Fundraising Fox
Talawar
1 known investors
Find your way into Talawar
Sign up to see every warm intro you have to Talawar
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Talawar team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Talawar Therapeutics develops bispecific antibodies that combine two disease-driving pathways in a single therapy for greater and more durable treatment effect. Its lead program, TALA-125, is an anti-IL-13 x anti-IL-18 bispecific aimed at first-line patients and those who have failed prior therapies.
Founders & leadership
Investors · 1
Access Biotechnologylisted by Access BiotechnologyNew York
How we know: Access Biotechnology's portfolio page · funding news · Not right? Tell us
Funding
SEC filings, press & company announcements- Undisclosed amountPIPEJun 2026Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Talawar do?
- Talawar Therapeutics develops bispecific antibodies that combine two disease-driving pathways in a single therapy for greater and more durable treatment effect. Its lead program, TALA-125, is an anti-IL-13 x anti-IL-18 bispecific aimed at first-line patients and those who have failed prior therapies.
- Who are Talawar's investors?
- Talawar's investors include Access Biotechnology.